NGF replacement therapy turned out to be an effective disease-modifying treatment to improve the cholinergic deficits in humans affected from mild AD and, then, to prevent and/or delay the cognitive deterioration of symptomology (Tuszynski et al., 2005; Mufson et al., 2008). Here, NGF is linked to Alzheimer disease.